-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Autoimmune uveitis (AU) is a chronic inflammatory disease affecting eye tissues, including the retina and retinal vessels, and is the fifth most common cause
of blindness worldwide.
Experimental autoimmune uveitis (EAU) is a widely used T-cell-mediated AU model that is immunoinduced by using the photoreceptor retinoid-binding protein 1-20 (IRBP 1-20) in an
adjuvant environment.
Chloroquine (CQ) and its hydroxy-group analogue, hydroxychloroquine (HCQ), are low-cost antimalarial drugs with few side effects and have been used for half a century
.
Hydroxychloroquine (HCQ) reduces inflammation of the retina in experimental autoimmune uveitis (EAU):
Methods: C57BL/6J mice were immunized with retinoid-binding protein 1-20 (IRBP 1-20) to induce EAU, and then treated
with vector or HCQ (100 mg/kg/day).
Hydroxychloroquine (HCQ) reduces inflammation caused by inflammation of retinal vascular endothelial cells (RVEC) dysfunction:
Results: HCQ therapy protects mice from uveitis, which can be demonstrated
by a decrease in the expression of inflammatory factors, chemokines, and adhesion molecules in the retina.
Hydroxychloroquine (HCQ) regulates TNF-α-stimulated endothelial dysfunction by the LOX-1/NF-κB axis:
In summary, the therapeutic effect of HCQ on uveitis is demonstrated
.
References: Hu Y, Li Z, Chen G, Li Z, Huang J, Huang H, Xie Y, Chen Q, Zhu W, Wang M, Chen J, Su W, Chen X, Liang D.
